Egbert Frederik S.
- Country
- The Netherlands
- Department
- Pulmonology
Research Overview
- Phase 2 Study of Pembrolizumab, MK-1084, and Combination Therapy in Patients With Advanced or Metastatic KRAS G12C-Mutant Nonsquamous Non-Small Cell Lung Cancer
- Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with Non-Small Cell Lung Cancer
- Phase 2 Open‑Label Multicohort Study of Rinatabart Sesutecan Monotherapy in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 40 of 163 partner sites.
Specializations
Advanced Lung Cancer Research
The investigator specializes in treating various forms of non-small cell lung cancer (NSCLC), with particular emphasis on cases involving specific genetic mutations including EGFR mutations, ALK-positive variants, and KRAS G12C mutations.
- Advanced and Metastatic NSCLC
- EGFR-Mutated Lung Cancer
- Brain Metastases in NSCLC
Their work encompasses both early-stage and advanced disease states, including cases with brain metastases.
Targeted Therapy Applications
The investigator focuses on developing and implementing targeted therapeutic approaches for lung cancer treatment, particularly evaluating novel drug combinations and personalized treatment strategies.
- Mutation-Specific Treatments
- Combination Therapy Protocols
- Immunotherapy Integration
Special attention is given to treatment resistance patterns and innovative therapeutic solutions.
Solid Tumor Expertise
Beyond lung cancer, the investigator's scope extends to various advanced solid tumors, including those with specific genetic alterations such as HER2 aberrations and SMARCA4 mutations.
- Multiple Cancer Types
- Genetic Mutation Analysis
- Novel Treatment Approaches
Their research encompasses various solid tumor types requiring specialized therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.